Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2008

View Archived Issues

Vertex updates progress of key pipeline candidates

GSK-690693 safe, inhibits AKT in a first-in-human study

ANG-1005 allows transport of paclitaxel to the brain

Thapsigargin analogue developed as a treatment for cancer

PCI-27483 active against lung and pancreatic cancer in vivo

New ROCK inhibitor developed at Inspire for the treatment of ocular hypertension

DiaKine and Kinexum to jointly develop new combination therapy for type 1 diabetes

Recent Leland Stanford patent discloses new therapeutic agents for autoimmune diseases

CSIRO and Oncaidia enter agreement to make Apomab suitable for human trials in cancer

Regulus obtains rights from Stanford for microRNA to regulate immune responses

Mycamine approved by EMEA for Candida infections

CD8+ T-cell responses seen with cancer vaccine with GM-CSF DNA as adjuvant

APC-8024 induces immune responses in patients with HER-2/neu expressing cancers

Obovatol effects on vascular smooth muscle cells studied in rats with carotid artery injury

Astellas receives FDA approvable letter for FK-506 modified release formulation

Menarini submits regulatory filing for Factive in Europe

Taflotan approved in Denmark for glaucoma and ocular hypertension

Poniard completes enrollment in phase II clinical trial of picoplatin in colorectal cancer

LifeCycle reports positive data from phase II program for LCP-AtorFen in mixed dyslipidemia

Pluristem's preclinical study synopsis of PLX-PAD receives U.S. and German approval

New treatment options for thrombotic disorders described in recent patents

Bayer and Regeneron dose first patient in second phase III VEGF Trap-Eye study

Genzyme reports preliminary results for novel oral candidate for Gaucher's disease

Trubion and Wyeth initiate phase IIb TRU-015 study in rheumatoid arthritis

Nymox announces that 3 year follow-up study of NX-1207 for BPH is near completion

Virobay reports novel agents for rheumatoid arthritis in a recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...